MDACC Study No:SWOGS0777 ( NCT No: NCT00644228)
Title:A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant
Principal Investigator:Donna M. Weber
Treatment Agent:Bortezomib; Dexamethasone; Lenalidomide
Study Status:Closed
Study Description:Unavailable
Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase III
Treatment Agents:Bortezomib
Treatment Location:Both at MDACC & Community Programs (CCOP/Network)
Estimated Length of Stay in Houston:None
Supported By:Southwest Oncology Group
Return Visit:Arm 1: RTC weekly for Cycle 1, every other week during cycles 2-6.
Arm 2: RTC twice a week for the first 2 weeks of each cycle and then once
during week 3 of each cycle.
During the maintenance phase patients will RTC monthly.
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Donna M. Weber
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults